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Abstract 
In 2005, an activating mutation in the Janus
kinase 2 (JAK2) was identified in a significant
proportion of patients with myeloproliferative
neoplasms, mainly polycythemia vera, essen-
tial thrombocythemia and primary myelofibro-
sis. Many types of mutations in the JAK-STAT
pathway have been identified, the majority are
related to JAK2. Currently JAK2 mutations are
important in the area of diagnosis of myeloid
neoplasms, but its role beyond the confirma-
tion of clonality is growing and widening our
knowledge about these disorders. In addition
to that, clinical trials to target JAK2-STAT path-
way will widen our knowledge and hopefully
will  offer  more  therapeutic  options.  In  this
review, we will discuss the role of JAK2 abnor-
malities in the pathogenesis, diagnosis, classi-
fication, severity and management of hemato-
logic neoplasms.
Introduction
For  decades  the  diagnosis,  classification
and  management  of  hematologic  neoplasms
was based on the clinico-pathological features
of these disorders. Major progress in both the
therapeutics and our understanding of these
diseases  did  not  occur  until  1960  when
Philadelphia chromosome was found in bone
marrow cells of patients with chronic myeloge-
nous leukemia (CML), followed by the identifi-
cation of the molecular defect by the fusion of
BCR and ABL genes in 1982. Fifteen years later
imatinib,  an  ABL  tyrosine  kinase  (TYK)
inhibitor,  was  developed  in  the  late  1990s.
Nowadays the diagnosis of CML is dependent on
the  identification  of  t(9;22)  (q34;q11)  or
BCR/ABL fusion gene and imatinib is one of its
first line therapeutics. Other hematologic neo-
plasms  are  tracking  the  footprints  of  CML.
BCR/ABL  negative  myeloproliferative  neo-
plasms (MPNs), particularly the classical poly-
cythemia vera (PV), essential thrombocythemia
(ET) and primary myelofibrosis (PMF), are cur-
rently drawing the attention of many scientists
in the fields of hematology, oncology, pathology,
genetics and pharmacology, after the identifica-
tion of Janus kinase 2 (JAK2) mutation in a sig-
nificant number of patients diagnosed for these
disorders in 2005.
1
In this article, our aim is to review the role
of  JAK2  abnormalities  in  the  pathogenesis,
diagnosis, classification, severity and manage-
ment of hematologic neoplasms.
Classification of myeloid neo-
plasms
As JAK2 abnormalities are mainly identified
in myeloid neoplasms, we will summarize the
current classification scheme for these disor-
ders. In general they are divided into 3 major
groups: acute leukemia, chronic leukemia and
myelodysplastic syndrome. Chronic leukemia
can be sub-divided into BCR/ABL positive or
negative,  those BCR/ABL  positive  will  be
labeled  as  CML  regardless  of  their  clinico-
pathological features unless it is presenting as
acute leukemia, while those BCR/ABL negative
will  be  divided  further  into  classical  MPNs,
non-classical MPNs with or without dysplasia,
and myelodysplastic syndrome (MDS) (Figure
1). The diagnosis and classification of these
disorders  are  based  on  peripheral  blood
counts,  blast  percentage,  type  of  myelosis,
presence  of  significant  dysplasia,  extent  of
fibrosis,  clinical  features,  biochemistry  and
most importantly genetics.
2-4
JAK2 abnormalities are not only associated
with most of the classical myeloid neoplasms
but they are also seen in association with other
myeloid  neoplasms  except  BCR/ABL positive
CML and acute lymphoid leukemia (ALL) where
it is only rarely reported as we will see later on.
One of the interesting things regarding the
clinical features of myeloid neoplasms is their
tendency to transform to acute leukemia; the
classical  MPNs,  beside  their  pre-leukemic
behavior, progress and regress to each other
(Figure 2).
3-5
So, why does an abnormal gene give rise to
different  disorders?  Why  do  classical  MPNs
progress and regress? What are the roles of
JAK2 abnormalities  in  the  pathogenesis  of
hematologic neoplasms?
JAK family
Janus kinase is a family of intracellular non-
receptor  tyrosine  kinases  that  transduce
cytokine-mediated signals. At present, it con-
sists  of  4  members:  JAK1,  JAK2,  JAK3  and
TYK2.
6
Janus  kinases  was  named  after  Janus  or
Ianus who in Roman mythology was believed to
be the God of gates, beginnings and endings.
He was imagined as having two faces or heads
facing in opposite directions.
7
Indeed,  Janus  kinases  are  located  just
beneath the cellular receptors to control the
signal  transmission  downstream  and  have
seven domains, two of which are structurally
similar. One of these (JH1) is an activating
domain while the other (JH2) seems to exert
an inhibitory effect (Figure 3).
Upon ligand binding to its specific receptor,
JAK protein will be activated and it will then
phosphorylate the downstream signaling mole-
cules like STATs, which will be actively trans-
ported  to  the  nucleus  where  it  will  activate
transcription factors (Figure 4). 
Abnormalities in JAK1 have been reported
in ALL of mainly T cell type where it is found in
nearly  20%  of  the  cases,
8 JAK2 is  found  in
myeloid neoplasms and rarely rearranged in
ALL,
6 JAK3 have been reported in more than
50%  of  transient  abnormal  myelopoiesis  in
Down  syndrome  patients,  acute  myeloid
leukemia (AML) megakaryoblastic type (M7)
and in some cases of severe combined immune
deficiency (SCID),
9-11 and TYK2 might have a
role in lymphoid neoplasms and natural killer
cell functional defects.
12
JAK2
JAK2 was mapped on the short arm of chro-
mosome 9p24 in 1992 by Pritchard and his
colleagues,
13 It has 140 kb spanning 25 exons
to  form  1132  aminoacid  JAK2  protein.
14 It
works  as  a  signaling  molecule  for  many
cytokines  including:  INF-γ,
15 erythropoietin
(EPO),
16 prolactin,
17 thrombopoietin  (TMP),
G-CSF,  GM-CSF
18 and  IL-3
19 via  activating
many  signaling  pathways  like:  MAPK,  PI3,
16
ERK
20 and STATs.
14 PRV1 (CD177) and NF-E2
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also  appear  to  be  activated  and  over-
expressed by JAK2.
6 One of the most impor-
tant pathways that are activated by JAK2 is
STAT5 followed by activation of BCL-XL and
finally upregulation of BCL2 where the cell
will gain a survival advantage.
6
Types of JAK2 abnormalities
and pathogenesis
In general we can divide these into 4 cate-
gories:
4,21-25
A. Rearrangements
JAK2 can be rearranged to:
- TEL/ETV6: t(9;12) (p24;p13) reported in 
some CML like MPNs and T-cell ALL;
- BCR: t(9;22) (p24;q11.2) reported in some
CML like MPNs;
- PCM1: t(8;9) (p22;p24) reported in some 
MPNs, AML and ALL;
- NF-E2: der(9) t(9;12) (p24;q13) reported 
in some cases of MDS.
B. Point mutations
- V617F G >T at nucleotide 1849 on exon14,
reported in mainly the classical MPNs;
- T875N reported in AML (M7);
- R683G and less frequently other R683 
point mutations reported in 18-28% of ALL
in Down syndrome patients and 10% of a 
high-risk cohort of childhood ALL in 
patients without Down syndrome.
C. Deletions/Insertions
- Exon12: there are more than eight 
reported mutations including deletions 
and insertions in 538 to 543 codons report
ed in 4% of PV cases;
- IREED del which is a five amino acids dele-
tion in JH2 pseudokinase domain reported
in B-cell ALL in Down syndrome patients.
D. Numerical
- It can present as trisomy (+9) or be over-
expressed due to amplification.
The  majority  of  these  abnormalities  are
affecting  the  JH2  domain  leading  to  loss  of
inhibitory effects on JH1 domain, hence the
later  will  be  auto-activated.  Suppressors  of
cytokine signaling (SOCS) 1 and 3 are nega-
tive regulators for JAK2 kinase, these suppres-
sors will also be phosphorylated and stabilized
by  the  hyperactive  tyrosine  kinase.
26 SOCS3
promoter methylation is another mechanism
that is found in a group of patients.
27
It is reported that 5-10% of MPN patients
have at least one relative who is affected by
this disorder, and in familial MPNs the risk of
developing these disorders increases 6-fold.
6,28
Recent studies suggest that particular single
nucleotide polymorphisms (SNP) are associat-
ed with a higher risk of developing JAK2 V617F
mutation. Out of about 659 SNPs, rs10974944
and rs12343867 are reported in 77% and 85%
in  association  with  JAK2 V617F  mutation
Review
Figure 1. The cur-
rent  classification
of  myeloid  neo-
plasm.  CNL:
chronic  neutro-
philic  leukemia,
CMML:  chronic
myelomonocytic
l e u k e m i a ,
JCMML:  juvenile
myelomonocytic
leukemia,  aCML:
atypical  chronic
m y e l o g e n o u s
leukemia. 
Figure 2. The rate
of  progression  of
chronic  myeloid
neoplasms  to
leukemic  phase.
Pre:  pre-fibrotic
stage  of  PMF  and
u n e x p l a i n e d
thrombotic  events
prior to the devel-
opment of MPN.
Figure 3. The structure of Janus kinases
Figure 4. Steps of JAK-STAT pathway.
AML Chronic neoplasms
BCR/ABL +ve BCR/ABL -ve
Classical
ET
PV
PMF
CNL
CMML
JCMML
aCML
Eosinophilia
Mastocytosis
Classical
Fibrosis
Neutrophilia
Monocytosis
Increased megaka
Non classical MPN
MPN/MDS
MDS
MDS
CML
ET PV
PMF
AML
ALL
2-95%
2-5%
2-15% 5-30%
1-2% 3-15%
15-20%
Pre
1 Ligand
JAK
JAK
STAT
Activated
JAK
Dimerized
STATs
Activation of 
transcription factors  
Phosphorylated STAT
P
P
P
P
Ligand
Ligand 23
Rec. cytogen. abnormalities
≥20% blasts[page 58] [Hematology Reviews 2009; 1:e10]
respectively,  with  a  significant  difference  if
compared to wild-type JAK2.
29
Prevalence of JAK2 abnormali-
ties in hematologic neoplasms
JAK2 V617F  mutation  is  reported  only  in
myeloid neoplasms with a high frequency in PV,
ET, PMF and refractory anemia with ring sider-
oblast and thrombocytosis (RARS-t). It is rarely
reported in CML,
30 but not in ALL or molecularly
characterized eosinophilic neoplasms and mas-
tocytosis,  i.e.  those  with  abnormalities  in
PDGFRA,  PDGFRB,  FGFR1 or  KIT.  JAK2
rearrangements are seen in some cases of AML,
atypical CML and ALL, while exon 12 mutations
are only reported in PV (Table 1).
3,4,31,32 
Screening and quantification
tests
Detecting JAK2 mutations, determination of
hetero-or homozygosity, and the allele burden,
i.e. the ratio of the mutant allele to the wild-
type, are the aims of carrying out molecular
studies.  Variable  screening  techniques  are
available  and  these  are  basically  utilizing
direct sequencing, allele specific polymerase
chain reaction (PCR) analysis or ultra sensi-
tive PCR techniques with variable sensitivities
that can detect mutant gene at the levels of
20%,  3%  and  0.01%,  respectively.  However,
quantification  techniques  are  preferred  in
order to estimate the mutant allele burden, to
monitor the disease course and effect of thera-
peutics.  Peripheral  blood  and  bone  marrow
samples,  frozen  plasma  and  paraffin-embed-
ded trephine bone marrow biopsies can all be
used.
2,33 Eric Lippert and his colleagues studied
the  concordance  of  assays  designed  for  the
quantification of JAK2 V617F and reported the
highest sensitivity by using Taqman allele spe-
cific  PCR  with  reverse  and  forward  primers
with  detection  sensitivity  up  to  0.2%  and
0.15%, respectively. But they found these tech-
niques laborious, having false positive results
and they were, as expected, capable of detect-
ing only the mutation of interest. On the other
hand,  they  found  pyrosequencing  and  direct
DNA sequencing to be the least sensitive, lim-
ited to the level of 2% and 5%, respectively, but
still  having  the  advantage  of  detecting  new
mutations.
34 It  has  recently  been  suggested
that immunoprecipitations and Western blot-
ting to test for SOCS3 tyrosine phosphorylation
may be a novel bio-marker of MPNs resulting
from a JAK2 mutation and a potential reporter
of effective JAK2 inhibitor therapy currently in
clinical development.
26
The roles of JAK2 abnormali-
ties in hematologic neoplasms
Confirmation of clonality
The  long  list  of  congenital,  secondary  or
reactive causes for cytosis, cytopenia and dys-
plasia is creating difficulties in labeling cases
for neoplastic conditions without ruling them
out, a process that requires extensive investi-
gation steps not to mention the time needed to
confirm persistence. Confirming clonality can
bypass all these issues and can solve the prob-
lematic cases in which a neoplastic condition
is co-existing with a secondary or congenital
cause. Many methods are used to detect clonal-
ity but the most dependable is by performing
cytogenetic, fluorescence in situ hybridization
(FISH)  and/or  molecular  tests.  Abnormal
immunophenotype and loss of X-linked poly-
morphism have many limitations in MPNs. It
is  currently  widely  accepted  that  detecting
JAK2 mutation, particularly V617F mutation, is
a major criterion in diagnosing myeloid neo-
plasms, especially MPNs. It is now incorporat-
ed in the WHO 2008, Nordic 2007, and BCSH
2007 classifications.
3,35,36
Phenotype and lineage determina-
tion
JAK2 abnormalities are seen in many types
of hematologic neoplasms as mentioned earli-
er, and also are reported in 70-80% of cases
with unexplained hepatic venous thrombosis
without  overt  neoplasms.
37 Not  only,  V617F
mutation  alone  is  seen  in  a  wide  range  of
myeloid  neoplasms.  This  fact  has  created
much hypothesis regarding the pathophysiolo-
gy of these neoplastic conditions to the extent
that some authors suggest that some disorders
are in fact phases of a single disease. Many
factors possibly play a role (Figure 5).
The type of abnormality
Some  abnormalities  are  only  reported  in
myeloid  neoplasms.  These  are  JAK2
rearrangements  to  BCR:  t(9;22)  and  NF-E2:
der(9)t(9;12), V617F and T875N point muta-
tions  and  exon  12  mutations.  On  the  other
hand, R683G and IREED del are reported in
lymphoid disorders. While rearrangements to
TEL/ETV6:  t(9;12)  and  PCM1:  t(8;9)  are
reported  in  both  lineages.  Some  of  these
abnormalities  are  only  reported  in  a  single
entity (Table 1).  
The targeted cell or receptor
It is suggested that the phenotype is deter-
mined by the ability of the affected stem cells
to differentiate into different lineages, and on
the  receptor  affected  by  the  mutation.  For
example, EPO, TMP, G-CSF or GM-CSF recep-
tors are targeted to give PV, ET, PMF or chron-
ic  myelomonocytic  leukemia,  respectively.
38
Another  example  is  the  identification  of
homozygous JAK2 V617F  mutation  in  the
endothelial cells in the vessels of PV patients
with Budd-Chiari syndrome.
39
Review
Table 1. Prevalence of JAK2 abnormalities in hematologic neoplasms.
Neoplasms JAK2 V617F mutation Other JAK2 abnormalities
Polycythemia vera >95% 4% JAK2exon12 mutation
Essential thrombocythemia 50-60%
Idiopathic myelofibrosis 40-50%
Chronic neutrophilic leukemia 20%
Chronic myelomonocytic leukemia 3-13%
Juvenile chronic myelomonocytic leukemia  20%
Atypical chronic myeloid leukemia 20% JAK2rearrangement, t(8;9), t(9;12), t(9;22) 
MPN/MDS-U 12-20%
MPN/MDS (RARSt) 50-70%
Myelodysplastic syndrome (RAEB,-5q) 1-7% JAK2rearrangement, t(9;12)
Secondary AML 4% JAK2rearrangement, t(8;9)
AML (M6) Few reported cases
AML (M7) 15% JAK2T875N
Mastocytosis 0-25% JAK2rearrangement, t(8;9), t(9;12)
Eosinophilic neoplasms 0-2%
Chronic myelogenous leukemia Rare reported cases
ALL Non JAK2rearrangement, t(8;9), 
t(9;12), JAK2R683G and less 
frequently other R683 point mutations
ALL in Down syndrome patients Non JAK2R683G, IREED del,  
other point mutations, insertions and deletions[Hematology Reviews 2009; 1:e10] [page 59]
Genetic background of the patient
Gender is one of the possible determinants,
as  ET  tend  to  occur  in  females  more  than
males, while the opposite is true of PV. Iron
metabolism is another factor, as iron depletion
will lead to ET phenotype rather than PV. The
opposite picture will be seen in relation to EPO
bioavailability. SNPs are another possible par-
ticipant as rs10974944 is significantly seen in
patients with PV if compared to ET.
4,29,38
Dosage effect
This appears to be the most important fac-
tor, and it can be explained by different thresh-
olds of JAK2 kinase activity at which variable
receptors, cytokines and proteasomes need to
react. This is supported by the reported results
of  homozygous  JAK2  V617F  mutation  occur-
ring in 25-30% PV compared to 2-4% in ET. Few
cases  are  reported  that  demonstrate  dosage
dependent phenotype, like those transforming
from  ET  to  PV  with  increasing  JAK2  V617F
mutation burden, or from PMF to PV with bur-
den  reduction  after  treatment  with  hydrox-
yurea (HU).
40 We have also encountered a case
of PMF that transformed to ET after treatment
with  HU  (K  Alkhairi,  KM  Alayed,  MK
Alabdulaali, unpublished data, 2007) By moni-
toring allele burden it is found that JAK2V617F
mutation  burden  is  increasing  significantly
from ET, PV to PMF.
6,38,40-44 The levels at which
the burden is found seem to correspond to a
specific phenotype of 25%, 55%, 50% and 60%
for ET, PV, PMF and post ET or PV myelofibro-
sis,  respectively.
43 Hypermethylation  of  the
SOCS3 promoter was identified in nearly 1/3 of
patients with myelofibrosis and in both JAK2
mutation positive and negative cases,
27 but not
in  other  types  of  MPNs;  this  again  will
strengthen the role of dosage effect. 
Pre-JAK2 mutation event
Several  findings  raise  the  possibility  of  a
pre- JAK2 mutation event leading or participat-
ing in the development of neoplasia: the pres-
ence  of  JAK2 mutation  negative  MPNs  with
25%  abnormal  cytogenetics,  the  finding  that
50% of JAK2 mutation positive cases are seen
with recurrent cytogenetic abnormalities, and
more interestingly, that the majority of  JAK2
mutation positive cases develop JAK2 mutation
negative leukemic blasts when they progress to
AML.
4,6,38,45 Some of the cytogenetic abnormali-
ties are suspected to present more in associa-
tion with JAK2 mutation to develop a specific
phenotype like del 20q in cases with PV.
4
Clinical severity and progression
Thrombosis,  bleeding,  splenomegaly,  bone
marrow  failure  and  evolution  to  acute
leukemia are the main complications of MPNs.
In ET, many studies suggested that JAK2 muta-
tion positive cases have a higher risk of devel-
oping venous thrombosis compared to patients
with wild-type JAK2. In a systematic literature
review, Panayiotis D. Ziakas analyzed 17 stud-
ies  with  2,905  ET  patients,  of  whom  1,646
(65.7%) patients were JAK2 V617F mutation
positive.  Thrombotic  events  occurred  in  523
(31.8%) of mutation positive cases and in 255
(20.3%)  of  patients  with  wild-type  JAK2.
Finally, he concluded that JAK2 V617F patients
have  a  2-fold  risk  of  developing  thrombosis
(OR  1.84,  95%CI  1.40-2.43).
46 Presence  of
inherited thrombophilia can increase the real-
tive risk of the development of thrombosis in
patients <60 years of age with ET and JAK2
V617F mutation from 2.23 (95%CI 1.57-3.18) to
7.66  (95%CI  2.66-22.03).
47 High  mutation
dosage are significantly associated with larger
spleen size, higher WBC count, higher lactate
dehydogenase (LDH) level and higher risk of
developing venous thrombosis or cardiovascu-
lar events in patients with ET or PV. However,
these findings are not sufficient for chemical
cytoreduction  intended  risk  stratification
which is still dependent on age, prior throm-
botic  event  and  cardiovascular  event-related
risk factors.
2,4,41,48
It  is  still  debatable  whether  an  increased
JAK2 mutation  burden  is  associated  with
increased risk of evolution to acute leukemia.
However, there is good evidence of its associa-
tion with progression from ET to PV to PMF. If
evolution  to  leukemia  then  occurs,  in  the
majority  of  cases  the  leukemic  cells  will  be
JAK2 mutation negative as mentioned earlier.
The  overwhelming  blasts  will,  therefore,
reduce the allele mutation burden which might
be considered a sign of evolution if it is not
related  to  chemical  cytoreductive  therapy
(Figure 6).
41,44
JAK2 as a therapeutic target
For  decades,  the  treatment  options  for
patients with MPNs was limited to palliation
and preventive measures against the develop-
ment of thrombosis using aspirin, phlebotomy,
splenectomy,  splenic  radiation  or  the  use  of
steroids, androgens or EPO in patients with
PMF.
1Since the middle of the 20
thcentury, aims
are widening and touching the areas of pre-
vention of leukemic transformation and cure
with the use of cytoreductive medications like
busulfan,  HU  and  interferon-alpha  (INF-α),
Review
Figure 5. Factors that might
determine the phenotype of
JAK2  mutation  positive
disorders.
Figure 6. JAK2 mutation burden during progression of MPNs. AL: acute leukemia, ET:
essential thrombocythemia, MF: myelofibrosis, PMF: primary myelofibrosis, PV: poly-
cythemia vera. 
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together with the trials of stem cell transplan-
tation. But the use of these options always car-
ries the risk of leukemogenesis. So, given the
fact that MPNs are very slow progressing disor-
ders and most of the patients are kept under
strict  control  with  non-chemical  approaches,
the use of these options is limited to high-risk
patients. 
In the last decade, the use of tyrosine kinase
inhibitors is expanding in the management of
hematologic  neoplasms,  especially  after  the
successful results of imatinib in CML patients.
However, the use of imatinib in MPNs is only
achieving limited benefits. It is reported that
the use of oral imatinib in PV can reduce the
need  for  phlebotomy  and  spleen  size,  while
parenteral administration can achieve remis-
sion in 22% of cases.
1,4,49 Currently, there are
many  trials  of  new  agents  on  patients  with
PMF,  including farnesyl transferase, the auro-
ra family of serine/threonine kinases, vascular
endothelial  growth  factor  (VEGF)  tyrosine
kinase,  proteasome  and  fibrogenesis
inhibitors, VEGF neutralizing antibodies and
GX15-070MS, an antagonist of the BH3-bind-
ing groove of the Bcl-2 family.
1,4
Many  specific  JAK2  inhibitors,  like
INCB018424, TG101209, TG101348, XL019 and
TG10134841, are currently in phase I/II trials
on advanced stages of MPNs l such as PMF,
post-ET  or  PV  myelofibrosis.  Recent  reports
from the trials with INCB018424 are showing
significant improvement in splenomegaly, con-
stitutional symptoms, control of myeloprolifer-
ation and reduction in allele burden. Non-spe-
cific JAK2 inhibitors are also in clinical trials.
These include: CEP-701 (an FLT3 inhibitor),
tipifarnib  (a  farnesyltransferase  inhibitor),
ITF2357 (an HDAC inhibitor) and hypomethy-
lating  agents.  The  main  drawbacks  of  JAK2
inhibitors are hematologic toxicity like neu-
tropenia and thrombocytopenia, non-hemato-
logic side effects which are mainly immuno-
logical and endocrinological. Beside that, cur-
rently used therapeutic options are well toler-
ated, and pegylated INF-α and parenteral ima-
tinib are reported to achieve 18-22% remission
rates, respectively. Another unpromising issue
is the limitation in curing the disease or pre-
venting  evolution  in  the  presence  of  a  pre-
JAK2 mutation event and JAK2 mutation nega-
tive  leukemic  transformation.  The  develop-
ment of resistance in vitro is another worrying
issue.
1,4,6,48-50 For the anticipated toxic effects of
JAK2 inhibitors, few agents targeting compo-
nent downstream of JAK2 are currently inves-
tigated like those inhibiting BCL-XL or SOCS1
mimetics.
1 
Conclusions 
JAK2 abnormalities are important contribu-
tors but not the sole events in the development
of hematologic neoplasms particularly MPNs.
Its  mutations,  rearrangements  or  del  are
important to confirm clonality, and their type
and dosage can help in classifying hematolog-
ic  neoplasms.  Currently,  JAK2 abnormalities
are mainly utilized in confirming clonality in
diagnosing classical BCR/ABL negative myelo-
proliferative neoplasms; however, we believe
that their role will expand to be added in more
hematologic neoplasms, to include the type of
JAK2 abnormality  in  the  sub-classifications
criteria and, possibly, to consider JAK2 muta-
tion burden in the process of classification and
in the assessment of transformation.   
The  JAK2  V617F  positive  MPNs  are  more
closely related and appear with variable clini-
co-pathological phenotypes in response to dif-
ferent modifiers. They seem to have a more
severe clinical course but there is still not suf-
ficient available data to include this mutation
in the risk stratification. 
JAK2/STAT pathway is an important target
for  new  therapeutics,  but  more  studies  are
needed to minimize their toxicity.
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